Tuesday, 19 February

08:00 – 09:30 Davos 2

Session 1: Arrhythmias

Chairs:
A. J. Camm, London
C. Sticherling, Basel

08:00 – 08:20

The new ESC Guidelines for the diagnosis and management of syncope

M. Brignole, Lavagna
08:20 – 08:40

Ablation of ventricular arrhythmias: state of the art

H. Calkins, Baltimore
08:40 – 09:00

Atrial fibrillation and HF: an evil conspiracy

J. Cleland, Glasgow
09:00 – 09:20

Risk stratification in ARVC

H. Calkins, Baltimore
09:20 – 09:30

Panel discussion

09:30 – 10:00

Coffee


10:00 – 11:30 Davos 2

Session 2: Atrial Fibrillation

Chairs:
H. Calkins, Baltimore
T. Reichlin, Berne

10:00 – 10:20

Medical therapy of AF

A. J. Camm, London
10:20 – 10:40

Pathophysiology and management of clinically silent AF

C. Brunckhorst, Zurich
10:40 – 10:55

Debate: Does ablation of AF change outcome? ─ Pro

G. Hindricks, Leipzig
10:55 – 11:10

Debate: Does ablation of AF change outcome? ─ Contra

M. Packer, Dallas
11:10 – 11:15

Rebuttal Pro

11:15 – 11:20

Rebuttal Contra

11:20 – 11:30

Panel discussion

12:00 – 13:15 Seehorn

Satellite Symposium Daiichi-Sankyo (a lunch bag will be offered)

ENGAGING Patients for DOAC Treatment


RCT, RWE and Guidelines: importance for clinical practice

A. J. Camm, London

Anticoagulation in high-risk patients

-Difficult to treat patients: Patients with moderate to severe renal impairment
Speaker: M. Namdar, Geneva
-DOACs in elderly and very elderly patients
S. Engelter, Basel
13:30 – 15:00 Davos 2

Session 3: Mitral and Tricuspid Valve Disease

Chairs:
R. Corti, Zurich
G. Pedrazzini, Lugano

13:30 – 13:50

Assessment of mitral valve function

J. J. Bax, Leiden
13:50 – 14:10

Mitral valve repair for secondary MR

F. Maisano, Zurich
14:10 – 14:30

Imaging to select patients for tricuspid transcatheter valve therapy

J. J. Bax, Leiden
14:30 – 14:50

Transcatheter treatment of tricuspid regurgitation ─ update on the novel devices

S. Windecker, Berne
14:50 – 15:00

Panel discussion

15:00 – 15:30

Coffee


15:00 – 16:30 Foyer

Poster Session: Heart Failure, Valve Disease, Imaging, Miscellaneous

Chair:
R. Binder, Wels

15:30 – 16:30 Schwarzhorn

Meet the Expert Session ─ Challenging Coronary Interventions

Panel:
F. Eberli, Zurich
R. Grocott-Mason, London
W. Wijns, Galway


Cases:
O. Gämperli, Zurich
P. Meier, Chur


15:30 – 16:30 Wisshorn

Meet the Expert Session ─ Atrial Fibrillation

Panel:
A. J. Camm, London
C. Brunckhorst, Zurich


Cases:
L. Haegeli, Aarau/Zurich
A. Breitenstein, Zurich 
V. Wilzeck, Aarau


15:30 – 16:30 Seehorn

Meet the Expert Session ─ Mitral Valve Disease

Panel:
J. J. Bax, Leiden
F. Maisano, Zurich


Cases:
R. Corti, Zurich
G. Pedrazzini, Lugano


16:30 – 17:30 Davos 2

Session 4: New ESC Guidelines

Chairs:
F. Cosentino, Stockholm
O. A. Smiseth, Oslo

16:30 – 16:50

Update of 2018 ESC Guidelines on pregnancy and CV disease

V. Regitz-Zagrosek, Berlin
16:50 – 17:10

ESC Guidelines on the diagnosis and treatment of PAD

I. Baumgartner, Berne
17:10 – 17:30

ESC Guidelines for the management of valvular heart disease

J. J. Bax, Leiden
16:30 – 17:30 Davos 1

Session 5: Devices in Heart Failure

Chair:
A. Breitenstein, Zurich
T. Suter, Berne

16:30 – 16:45

ESC Guidelines on devices in HF

P. Ponikowski, Wrozlaw
16:45 – 17:00

ICDs: indications and results

A. J. Camm, London
17:00 – 17:15

Which patients benefit from CRT?

J. Cleland, Glasgow
17:15 – 17:30

Which patients benefit from LVAD?

D. Milicic, Zagreb
17:45 – 18:45 Davos 2

Drugs in Heart Failure

Chairs:
J. Cleland, Glasgow
P. Ponikowski, Wrozlaw

17:45 – 18:05

Focus on comorbidities

M. A. Pfeffer, Boston
18:05 – 18:25

Use of new drugs in chronic HF according to guidelines

K. B. Swedberg, Gothenburg
18:25 – 18:45

New approaches in the treatment of HF

B. Pitt, Ann Arbor
19:30 – 22:30

Congress Dinner